Skip to main navigation Skip to search Skip to main content

MT2026-21: A Phase 1/2 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363 or KITE-753, Autologous Anti-CD19/CD20 CAR T-cell Therapies, in Subjects With Relapsed and/or Refractory B-cell Lymphoma (Palisades-1)

Project: Research project

Project Details

StatusActive
Effective start/end date6/15/26 → 6/30/36

Funding

  • KITE PHARMA, INC